On Cost Allocation in Steiner Tree Networks

Author(s):  
Darko Skorin-Kapov
2021 ◽  
pp. 2100141
Author(s):  
Haoyi Yu ◽  
Qiming Zhang ◽  
Benjamin P. Cumming ◽  
Elena Goi ◽  
Jared H. Cole ◽  
...  

Author(s):  
Julio R. Fernández ◽  
Inés Gallego ◽  
Andrés Jiménez-Losada ◽  
Manuel Ordóñez

AbstractCost-allocation problems in a fixed network are concerned with distributing the costs for use by a group of clients who cooperate in order to reduce such costs. We work only with tree networks and we assume that a minimum cost spanning tree network has already been constructed and now we are interested in the maintenance costs. The classic problem supposes that each agent stays for the entire time in the same node of the network. This paper introduces cost-allocation problems in a fixed-tree network with a set of agents whose activity over the nodes is fuzzy. Agent’s needs to pay for each period of time may differ. Moreover, the agents do not always remain in the same node for each period. We propose the extension of a very well-known solution for these problems: Bird’s rule.


2021 ◽  
Vol 8 (19) ◽  
pp. 2170127
Author(s):  
Haoyi Yu ◽  
Qiming Zhang ◽  
Benjamin P. Cumming ◽  
Elena Goi ◽  
Jared H. Cole ◽  
...  

2021 ◽  
Vol 122 ◽  
pp. 102888
Author(s):  
Han Zou ◽  
Maged M. Dessouky ◽  
Shichun Hu

1998 ◽  
Vol 80 (12) ◽  
pp. 887-893 ◽  
Author(s):  
Jacopo Gianetti ◽  
Gianfranco Gensini ◽  
Raffaele De Caterina

SummaryAims. The recent publication of two large trials of secondary prevention of coronary artery disease with oral anticoagulants (WARIS and ASPECT) has caused a revival of the interest for this antithrombotic therapy in a clinical setting where the use of aspirin is common medical practice. Despite this, the preferential use of aspirin has been supported by an American cost-effectiveness analysis (JAMA 1995; 273: 965). Methods and Results. Using the same parameters used in that analysis and incidence of events from the Antiplatelet Trialists Collaboration and the ASPECT study, we re-evaluated the economic odds in favor of aspirin or oral anticoagulants in the Italian Health System, which differs significantly in cost allocation from the United States system and is, conversely, similar to other European settings. Recalculated costs associated with each therapy were 2,150 ECU/ patient/year for oral anticoagulants and 2,187 ECU/patient/year for aspirin. In our analysis, the higher costs of oral anticoagulants versus aspirin due to a moderate excess of bleeding (about 10 ECU/ patient/year) and the monitoring of therapy (168 ECU/ patient/year) are more than offset by an alleged savings for recurrent ischemic syndromes and interventional procedures (249 ECU/ patient/year). Conclusions. Preference of aspirin vs. oral anticoagulants in a pharmaco-economical perspective is highly dependent on the geographical situation whereupon calculations are based. On a pure cost-effectiveness basis, and in the absence of data of direct comparisons between aspirin alone versus I.N.R.-adjusted oral anticoagulants, the latter are not more expensive than aspirin in Italy and, by cost comparisons, in other European countries in the setting of post-myocardial infarction.


2014 ◽  
Vol 9 (4) ◽  
pp. 854 ◽  
Author(s):  
Baseem Khan ◽  
Ganga Agnihotri ◽  
Pawan Rathore ◽  
Anuprita Mishra ◽  
Garima Naidu

Sign in / Sign up

Export Citation Format

Share Document